Results 11 to 20 of about 53,193 (289)

Selpercatinib for RET fusion-positive non-small cell lung cancer. [PDF]

Aust Prescr
/
europepmc   +3 more sources

Case report: Selpercatinib in the treatment of RET fusion-positive advanced lung adenocarcinoma: a challenging clinical case [PDF]

Frontiers in Oncology
BackgroundRearranged during transfection (RET) fusions represent a distinct molecular subset of non-small cell lung cancer (NSCLC) with targeted therapeutic potential.
Raffaella Pagliaro, Raffaella Pagliaro, Paola Maria Medusa, Paola Maria Medusa, Fabiana Vitiello, Luigi Aronne, Luigi Aronne, Susan F. M. Campbell, Susan F. M. Campbell, Fabio Perrotta, Fabio Perrotta, Andrea Bianco, Andrea Bianco   +12 more
doaj   +2 more sources

Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC [PDF]

Frontiers in Oncology
Over the past decade, molecular characterization has led to change the management of advanced non-small cell lung cancer (NSCLC) harboring driver mutations.
Elisa De Carlo, Elisa Bertoli, Elisa Bertoli, Monica Schiappacassi, Brigida Stanzione, Alessandro Del Conte, Roberto Doliana, Michele Spina, Alessandra Bearz   +8 more
doaj   +2 more sources

BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter study. [PDF]

ESMO Open
Schöffski P, Gazzah A, Trigo J, Italiano A, Gougis P, Subbiah V, Shih JY, Loong HH, Doger B, Keegan M, Jeglinski B, Andreas K, Cho BC.   +12 more
europepmc   +2 more sources

Cerebrospinal fluid ctDNA clarifies clonal divergence: leptomeningeal flare of <i>EGFR</i>-mutant disease after switch to selpercatinib for acquired <i>RET</i> fusion. [PDF]

J Liq Biopsy
Kunimasa K, Tamiya M, Inoue T, Mamesaya N, Tanaka T, Komuta K, Futamura S, Honma K, Nishino K.   +8 more
europepmc   +2 more sources

Neoadjuvant Chemotherapy With Selpercatinib for Locally Advanced <i>RET</i> Fusion-Positive Papillary Thyroid Carcinoma: A Case Report. [PDF]

Case Rep Endocrinol
Kadoya M, Masudo K, Ito H, Okubo Y, Miyagi Y, Hayashi H, Iwasaki H.   +6 more
europepmc   +3 more sources

Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset

Translational Oncology, 2023
Background: RET fusions are driver alterations in cancer and are most commonly found in non-small cell lung cancer and well-differentiated thyroid cancer. However, RET fusion have been reported in other solid tumors. Material and methods: A retrospective
Misako Nagasaka, Danielle Brazel, Yasmine Baca, Joanne Xiu, Mohammed Najeeb Al-Hallak, Chul Kim, Jorge Nieva, Jeffrey J. Swensen, David Spetzler, Wolfgang Michael Korn, Mark A. Socinski, Luis E. Raez, Balazs Halmos, Sai-Hong Ignatius Ou   +13 more
doaj   +1 more source

RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report

Frontiers in Oncology, 2023
Patients with metastatic pancreatic cancer have limited treatment options and a dismal prognosis. While RET fusion is rare (0.6%) in pancreatic cancer, the efficacy of RET-targeted treatment in patients with TRIM33-RET fusion has not been previously ...
Tongyi Zhang, Hongwei Wang, Zhiwei Cai, Siqi Zhang, Chongyi Jiang, Chongyi Jiang   +5 more
doaj   +1 more source

Targeted therapy of RET fusion-positive non-small cell lung cancer

Frontiers in Oncology, 2022
Lung cancer has very high morbidity and mortality worldwide, and the prognosis is not optimistic. Previous treatments for non-small cell lung cancer (NSCLC) have limited efficacy, and targeted drugs for some gene mutations have been used in NSCLC with ...
Zixiong Shen, Binxu Qiu, Lin Li, Bo Yang, Guanghu Li   +4 more
doaj   +1 more source

RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation

Disease Models & Mechanisms, 2021
Multi-kinase RET inhibitors, such as cabozantinib and RXDX-105, are active in lung cancer patients with RET fusions; however, the overall response rates to these two drugs are unsatisfactory compared to other targeted therapy paradigms.
Takuo Hayashi, Igor Odintsov, Roger S. Smith, Kota Ishizawa, Allan J. W. Liu, Lukas Delasos, Christopher Kurzatkowski, Huichun Tai, Eric Gladstone, Morana Vojnic, Shinji Kohsaka, Ken Suzawa, Zebing Liu, Siddharth Kunte, Marissa S. Mattar, Inna Khodos, Monika A. Davare, Alexander Drilon, Emily Cheng, Elisa de Stanchina, Marc Ladanyi, Romel Somwar   +21 more
doaj   +1 more source